Variable plasma/liver and tissue esterase hydrolysis of simvastatin in healthy volunteers after a single oral dose

Clinical Drug Investigation

Volumn 21, Issue 9, 2001, Pages 643-652

  Vree, T B ^a   Dammers, E ^b   Ulc, I ^c   Horkovics Kovats, S ^d   Ryska, M ^e   Merkx, I ^f  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DADA Consultancy   (Netherlands)

^c Cepha Sro   (Czech Republic)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Quinta Analytica   (Czech Republic)

^f Novartis   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ESTERASE; SIMVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HYDROLYSIS; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG TISSUE LEVEL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; PRIORITY JOURNAL; VALIDATION PROCESS;

EID: 0034773713     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200121090-00006     Document Type: Article

References (25)

1. A receptor-mediated pathway for cholesterol homeostasis
2. Regulation of the mevalonate pathway
3. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors
4. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors
5. The role of intestinal metabolism on bioavailability
6. Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferase in rat and human hepatic and extrahepatic tissues
7. Clinical pharmacokinetics and practical applications of simvastatin
8. Variable activation of lovastatin by hydrolytic enzymes in human plasma and liver
9. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin
10. Metabolic disposition studies on simvastatin, a cholesterol lowering prodrug
11. Regioselectivity stereoselectivity in the metabolism of HMG-CoA reductase inhibitors
12. In vitro comparative inhibition profiles of major drug metabolising cytochrome P450 isoenzymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors
13. Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue
14. Simvastatin, a reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia
15. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
16. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
17. 1980 Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-co-enzyme A reductase and a cholesterol-lowering agent
18. Lovastatin
19. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin
20. Liver and gut mucosa acetylation of mesalazine in healthy volunteers
21. Grapefruit juice-simvastatin interaction; effect on serum concentrations of simvastatin, simvastatin acid and HMG-CoA reductase inhibitors
22. Biotransformation of lovastatin. Identification of cytochrome P4503A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes